Myeloproliferative Neoplastic Diseases Observatory From Brest
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity Hospital, Brest
About this trial
All patients diagnosed or followed in Brest University Hospital for Philadelphia negative myeloproliferative neoplasms will be included in this observational study.
Myeloproliferative neoplasms recorded included: polycythemia vera, essential Thrombocythemia and Primary Myelofibrosis.
This is a not interventional study. Alive patients need to sign a non-opposition consent form.
Patients will be followed until last news (death, change of reference centre...).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with essentiel thrombocythemia, polycythemia vera or primary myelofibrosis
Signature of the non-opposition consent form
Disqualifiers
None
Trial population
Patients followed for essentiel thrombocythemia, polycythemia vera or primary myelofibrosis
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Overall Survival
occurrence of death
Time frame
10 yearsSecondary outcomes
1
Incidence of evolutions
occurrence of transformation into polycythemia vera, secondary myelofibrosis, myelodysplastic syndrome or acute leukemia
Time frame
10 years2
Incidence of thromboses
occurrence of arterial or venous thrombotic events
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov